Akari Therapeutics wins European patent for thailanstatin-based ADC payloads
PUBT · 05/12 12:35
Share
Listen to the news
- Akari Therapeutics secured a European patent covering Thailanstatin analogs used as RNA splicing modulator payloads for antibody-drug conjugates.
- European Patent No. 3684773B1 provides composition-of-matter protection for payload chemistry underpinning lead ADC AKTX-101, with claims designed to support use with multiple linker technologies.
- Patent strengthens IP position across major European markets, extending coverage to UK, Germany, France.
- AKTX-101, a TROP2-targeting ADC using Akari’s PH1 payload platform, remains in IND-enabling studies with Phase 1 first-in-human trial expected by mid-2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved